Ionis Pharmaceuticals IONS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Ionis Pharmaceuticals (IONS) Core Market Data and Business Metrics
Latest Closing Price
$28.71Price-Earnings Ratio
-9.44Total Outstanding Shares
158.97 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
2855 Gazelle Court, Carlsbad, CA, 92010
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,708,250 Shares | 7.5 | 3/14/2025 | 12,814,848 Shares |
| 2,018,209 Shares | 6.37 | 2/28/2025 | 12,853,622 Shares |
| 1,340,248 Shares | 9.46 | 2/14/2025 | 12,673,485 Shares |
| 1,831,301 Shares | 6.62 | 1/31/2025 | 12,124,536 Shares |
| 1,408,358 Shares | 7.27 | 1/15/2025 | 10,239,965 Shares |
| 1,682,606 Shares | 6.48 | 12/31/2024 | 10,901,561 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-156.92 Million |
| Net Cash Flow From Financing Activities | $478.06 Million |
| Net Cash Flow From Operating Activities, Continuing | $-500.95 Million |
| Net Cash Flow, Continuing | $-156.92 Million |
| Net Cash Flow From Financing Activities, Continuing | $478.06 Million |
| Net Cash Flow From Operating Activities | $-500.95 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Income Tax Expense/Benefit, Current | $-6.17 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss | $-453.90 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $-453.90 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-452.06 Million |
| Comprehensive Income/Loss | $-452.06 Million |
| Comprehensive Income/Loss Attributable To Parent | $-452.06 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $3.00 Billion |
| Fixed Assets | $94.25 Million |
| Current Liabilities | $309.32 Million |
| Wages | $69.61 Million |
| Noncurrent Liabilities | $2.11 Billion |
| Noncurrent Assets | $383.38 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||